Access the full text.
Sign up today, get DeepDyve free for 14 days.
Jiasheng Wang, Yong-xian Hu, He Huang (2018)
Current development of chimeric antigen receptor T-cell therapy.Stem cell investigation, 5
B. Dholaria, C. Bachmeier, F. Locke (2018)
Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related ToxicitiesBioDrugs, 33
N. Raje, J. Berdeja, Yi Lin, D. Siegel, S. Jagannath, D. Madduri, M. Liedtke, J. Rosenblatt, M. Maus, Ashley Turka, L. Lam, R. Morgan, Kevin Friedman, M. Massaro, Julie Wang, G. Russotti, Zhihong Yang, T. Campbell, K. Hege, F. Petrocca, Travis Quigley, N. Munshi, J. Kochenderfer (2019)
Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaThe New England Journal of Medicine, 380
A. Hirayama, J. Gauthier, K. Hay, J. Voutsinas, Q. Wu, T. Gooley, Daniel Li, S. Cherian, Xueyan Chen, B. Pender, R. Hawkins, A. Vakil, R. Steinmetz, Utkarsh Acharya, R. Cassaday, A. Chapuis, Tejaswini Dhawale, P. Hendrie, H. Kiem, R. Lynch, J. Ramos, M. Shadman, B. Till, S. Riddell, D. Maloney, C. Turtle (2019)
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.Blood, 133 17
M. Kenter, A. Cohen (2015)
The return of the prodigal son and the extraordinary development route of antibody TGN1412 ‐ lessons for drug development and clinical pharmacologyBritish Journal of Clinical Pharmacology, 79
L. Chatenoud, C. Ferran, A. Reuter, C. Legendre, Y. Gevaert, H. Kreis, P. Franchimont, J. Bach (1989)
Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected].The New England journal of medicine, 320 21
T. Hünig (2012)
The storm has cleared: lessons from the CD28 superagonist TGN1412 trialNature Reviews Immunology, 12
Susana Roselló, I. Blasco, L. Fabregat, A. Cervantes, Karin Jordan (2017)
Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.Annals of oncology : official journal of the European Society for Medical Oncology, 28 suppl_4
C. Turtle, L. Hanafi, C. Berger, T. Gooley, S. Cherian, M. Hudecek, D. Sommermeyer, Katherine Melville, B. Pender, Tanya Budiarto, E. Robinson, Natalia Steevens, Colette Chaney, L. Soma, Xueyan Chen, C. Yeung, B. Wood, Daniel Li, Jianhong Cao, S. Heimfeld, M. Jensen, S. Riddell, D. Maloney (2016)
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.The Journal of clinical investigation, 126 6
C. June, Roddy O’Connor, O. Kawalekar, S. Ghassemi, M. Milone (2018)
CAR T cell immunotherapy for human cancerScience, 359
J. Haanen, F. Carbonnel, C. Robert, K. Kerr, S. Peters, J. Larkin, K. Jordan (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 28 suppl_4
Roman Khadka, R. Sakemura, S. Kenderian, Aaron Johnson (2019)
Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.Immunotherapy, 11 10
L. Riegler, G. Jones, Daniel Lee (2019)
Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapyTherapeutics and Clinical Risk Management, 15
Joshua Hill, Daniel Li, K. Hay, Margaret Green, S. Cherian, Xueyan Chen, S. Riddell, D. Maloney, M. Boeckh, C. Turtle (2017)
Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.Blood, 131 1
K. Mahadeo, S. Khazal, H. Abdel-Azim, J. Fitzgerald, A. Taraseviciute, C. Bollard, P. Tewari, C. Duncan, C. Traube, D. McCall, M. Steiner, I. Cheifetz, L. Lehmann, Rodrigo Mejia, J. Slopis, R. Bajwa, P. Kebriaei, P. Martin, J. Moffet, J. McArthur, D. Petropoulos, Joan Curry, Sarah Featherston, Jessica Foglesong, B. Shoberu, A. Gulbis, M. Mireles, L. Hafemeister, C. Nguyen, N. Kapoor, K. Rezvani, S. Neelapu, E. Shpall (2018)
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapyNature Reviews. Clinical Oncology, 16
Adverse Drug Reaction Bulletin ISSN 0044-6394 is published bimonthly by Wolters Kluwer Health, Inc. and distributed in the US by Mercury Airfreight International Inc., 365 Blair Road
M. Norelli, B. Camisa, G. Barbiera, Laura Falcone, Ayurzana Purevdorj, M. Genua, F. Sanvito, M. Ponzoni, C. Doglioni, P. Cristofori, C. Traversari, C. Bordignon, F. Ciceri, Renato Ostuni, C. Bonini, M. Casucci, A. Bondanza (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cellsNature Medicine, 24
Daniel Lee, B. Santomasso, F. Locke, A. Ghobadi, C. Turtle, Jennifer Brudno, M. Maus, Jae Park, E. Mead, S. Pavletic, W. Go, L. Eldjerou, R. Gardner, N. Frey, K. Curran, K. Peggs, M. Pasquini, J. Dipersio, M. Brink, K. Komanduri, S. Grupp, S. Neelapu (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 25 4
S. Neelapu, F. Locke, N. Bartlett, L. Lekakis, D. Miklos, C. Jacobson, I. Braunschweig, O. Oluwole, T. Siddiqi, Yi Lin, J. Timmerman, P. Stiff, J. Friedberg, I. Flinn, A. Goy, B. Hill, Mitchell Smith, A. Deol, U. Farooq, P. Mcsweeney, J. Muñoz, I. Avivi, J. Castro, J. Westin, J. Chavez, A. Ghobadi, K. Komanduri, R. Levy, E. Jacobsen, T. Witzig, P. Reagan, A. Bot, J. Rossi, L. Navale, Yi-zhou Jiang, J. Aycock, M. Elias, David Chang, J. Wiezorek, W. Go (2017)
Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell LymphomaThe New England Journal of Medicine, 377
A. Shimabukuro-Vornhagen, P. Gödel, M. Subklewe, H. Stemmler, H. Schlößer, M. Schlaak, M. Kochanek, B. Böll, M. Bergwelt-Baildon (2018)
Cytokine release syndromeJournal for Immunotherapy of Cancer, 6
A. Hirayama, C. Turtle (2019)
Toxicities of CD19 CAR‐T cell immunotherapyAmerican Journal of Hematology, 94
Henry Marshall, M. Djamgoz (2018)
Immuno-Oncology: Emerging Targets and Combination TherapiesFrontiers in Oncology, 8
Summary Cytokine release syndrome (CRS) is an adverse drug reaction that is poorly understood but is likely to be increasingly common as more immunotherapeutics are being developed and licensed, principally in the treatment of cancer. Early recognition and aggressive treatment of this potentially rapidly fatal systemic inflammatory response syndrome (SIRS) is the key to a better outcome for this adverse drug reaction. aNational Institute for Health Research Guys and St Thomas’ Biomedical Research Centre bBritish Heart Foundation Centre, King's College London, UK Correspondence to Dr Henry Fok, Clinical Research Facility, 4th Floor, North Wing, St Thomas’ Hospital London, SE1 7EH, UK. Tel: +44 207188 4799; e-mail: henry.fok@kcl.ac.uk
Adverse Drug Reaction Bulletin – Wolters Kluwer Health
Published: Dec 1, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.